Targeting efficiency and biodistribution of biotinylated-EGF-conjugated gelatin nanoparticles administered via aerosol delivery in nude mice with lung cancer

Biomaterials

Volumn 29, Issue 20, 2008, Pages 3014-3022

  Tseng, Ching Li ^a   Wu, Steven Yueh Hsiu ^a   Wang, Wen Hsi ^a   Peng, Cheng Liang ^a   Lin, Feng Huei ^a   Lin, Chien Cheng ^a   Young, Tai Horng ^a   Shieh, Ming Jium ^a  

^a NATIONAL TAIWAN UNIVERSITY   (Taiwan)

Author keywords

Drug delivery; EGF; Gelatin; In vivo test; Lung cancer; Nanoparticle

Indexed keywords

AEROSOLS; DRUG DELIVERY; ENZYMES; RATS;

GELATIN; LUNG CANCER;

NANOPARTICLES;

AVIDIN; DRUG CARRIER; EPIDERMAL GROWTH FACTOR; GELATIN; MYELOPEROXIDASE; NANOPARTICLE;

AEROSOL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; BIOTINYLATION; CONTROLLED STUDY; DRUG CONJUGATION; DRUG DELIVERY SYSTEM; DRUG DISTRIBUTION; ENZYME ACTIVITY; FLUORESCENCE ANALYSIS; LUNG CANCER; LUNG EDEMA; MALE; MOUSE; NEBULIZATION; NONHUMAN; NUDE MOUSE; PRIORITY JOURNAL; SCANNING ELECTRON MICROSCOPY;

AEROSOLS; ANIMALS; BIOTIN; EPIDERMAL GROWTH FACTOR; GELATIN; LUNG NEOPLASMS; MALE; MICE; MICE, NUDE; MICROSCOPY, ELECTRON, SCANNING; NANOPARTICLES; TISSUE DISTRIBUTION;

MUS; MUS MUSCULUS;

EID: 42749095149     PISSN: 01429612     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.biomaterials.2008.03.033     Document Type: Article

References (37)

1. Koshkina N.V., Waldrep J.C., Roberts L.E., Golunski E., Melton S., and Knight V. Paclitaxel liposome aerosol treatment induces inhibition of pulmonary metastases in murine renal carcinoma model. Clin Cancer Res 7 (2001) 3258-3262
2. Cryan S.A. Carrier-based strategies for targeting protein and peptide drugs to the lungs. AAPS J 7 1 (2005) E20-E40
3. Kaul G., and Amiji M. Biodistribution and targeting potential of poly(ethylene glycol) modified gelatin nanoparticles in subcutaneous murine tumor model. J Drug Target 12 (2004) 585-591
4. Kim H.W., Park I.K., Cho C.S., Lee K.H., George R., Beck J., et al. Aerosol delivery of glucosylated polyethylenimine/phosphatase and tensin homologue deleted on chromosome 10 complex suppresses Akt downstream pathways in the lung of K-ras null mice. Cancer Res 64 (2004) 7971-7976
5. Suarez S., Gonzalez-Rothi R.J., Schreier H., and Hochhaus G. Effect of dose and release rate on pulmonary targeting of liposomal triamcinolone acetonide phosphate. Pharm Res 15 (1998) 461-465
6. Deaton A.T., Jones L.D., Dunbar C.A., Hickey A.J., and Williams D.M. Generation of gelatin aerosol particles from nebulized solutions as model drug carrier systems. Pharm Dev Technol 7 (2002) 147-153
7. Dailey L.A., Jekel N., Fink L., Gessler T., Schmehl T., Wittmar M., et al. Investigation of the proinflammatory potential of biodegradable nanoparticle drug delivery systems in the lung. Toxicol Appl Pharmacol 215 (2006) 100-108
8. Shek P.N., Suntres Z.E., and Brooks J.I. Liposomes in pulmonary applications: physicochemical considerations, pulmonary distribution and antioxidant delivery. J Drug Target 2 (1994) 431-442
9. Peppas N.A. An introduction to materials in medicine. In: Ratner B.D., Hoffman A.S., Schoen F.J., and Lemons J.E. (Eds). Biomaterials science (1996), Academic Press, New York 60-64
10. Morimoto K., Katsumata H., Yabuta T., Iwanaga K., Kakemi M., Tabata Y., et al. Gelatin microspheres as a pulmonary delivery system: evaluation of salmon calcitonin absorption. J Pharm Pharmacol 52 (2000) 611-617
11. Farivar A.S., MacKinnon-Patterson B., Barnes A.D., and Mulligan M.S. The effect of anti-inflammatory properties of mycophenolate mofetil on the development of lung reperfusion injury. J Heart Lung Transplant 24 (2005) 2235-2242
12. Coester C.J., Langer K., Briesen H.V., and Kreuter J. Gelatin nanoparticles by two step desolvation - a new preparation method, surface modifications and cell uptake. J Microencapsul 17 (2000) 187-193
13. Weber C., Reiss S., and Langer K. Preparation of surface modified protein nanoparticles by introduction of sulfhydryl groups. Int J Pharm 211 (2000) 67-78
14. Hermanson G.T. Antibody modification and conjugation: bioconjugate techniques (1996), Academic Press, San Diego
15. Tseng C.-L., Wang T.-W., Dong G.-C., Wu S.Y.-H., Young T.-H., Shieh M.-J., et al. Development of gelatin nanoparticles with biotinylated EGF conjugation for lung cancer targeting. Biomaterials 28 (2007) 3996-4005
16. Koshkina N.V., Agoulnik I.Y., Melton S.L., Densmore C.L., and Knight V. Biodistribution and pharmacokinetics of aerosol and intravenously administered DNA-polyethyleneimine complexes: optimization of pulmonary delivery and retention. Mol Ther 8 (2003) 249-254
17. Koshkina N.V., Kleinerman E.S., Waldrep C., Jia S.-F., Worth L.L., Gilbert B.E., et al. 9-Nitrocamptothecin liposome aerosol treatment of melanoma and osteosarcoma lung metastases in mice. Clin Cancer Res 6 (2000) 2876-2880
18. Knowles M., and Boucher R. Mucus clearance as a primary innate defense mechanism for mammalian airways. J Clin Invest 109 5 (2002) 571-577
19. Guyton A.C., and Hall J.E. Textbook of medical physiology. 9th ed. (2000), Harcour Asia Pte Ltd, Singapore
20. Zanen P., and Lammers J.W. Reducing adverse effect of inhaled fenoterol through optimization of the aerosol formulation. J Aerosol Med 12 (1999) 241-247
21. Dalby R., Tiano S., and Hickey A.J. Medical devices for the delivery of therapeutic aerosols to the lungs. Inhalation aerosols: physical and biological basis for therapy (1996), Marcel Dekker, Inc, New York
22. Schurch S., Gehr P., Im Hof V., Geiser M., and Green F. Surfactant displaces particles toward the epithelium in airways and alveoli. Respir Physiol 80 (1990) 17-32
23. Tsapis N., Bennett D., Jackson B., Weitz D.A., and Edwards D.A. Trojan particles: large porous carriers of nanoparticles for drug delivery. Proc Natl Acad Sci USA 99 (2002) 12001-12005
24. Nemmar A., Vanbilloen H., Hoylaerts M.F., Hoet P.H.M., Verbruggen A., and Nemery B. Passage of intratracheally instilled ultrafine particles from the lung into the systemic circulation in hamster. Am J Respir Crit Care Med 164 (2001) 1665-1668
25. MacNee W., and Donaldson K. How can ultrafine particles be responsible for increased mortality. Monaldi Arch Chest Dis 55 (2000) 135-139
26. Zhou Z., Kozlowski J., and Schuster D.P. Physiologic, biochemical, and imaging characterization of acute lung injury in mice. Am J Respir Crit Care Med 172 (2005) 344-351
27. Hoy A., Muller B.L., Kutter D., Siest G., and Visvikis S. Growing significance of myeloperoxidase in non-infectious diseases. Clin Chem Lab Med 40 (2002) 2-8
28. Geys J., Coenegrachts L., Vercammen J., Engelborghs Y., Nemmara A., Nemery B., et al. In vitro study of the pulmonary translocation of nanoparticles: a preliminary study. Toxicol Lett 160 (2006) 218-226
29. Nemmar A., Hoylaerts M.F., Hoet P.H.M., Dinsdale D., Smith T., Xu H., et al. Ultrafine particles affect experimental thrombosis in an in vivo hamster model. Am J Respir Crit Care Med 166 (2002) 998-1004
30. Nielsen U.B., Kirpotin D.B., Pickering E.M., Hong K., Park J.W., Shalaby M.R., et al. Therapeutic efficacy of anti-ErbB2 immunoliposomes targeted by a phage antibody selected for cellular endocytosis. Biochim Biophys Acta 1591 (2002) 109-118
31. Carlsson J., Blomquist E., Gedda L., Liljegren A., Malmstroerm P.-U., Stroerm A.S., et al. Conjugate chemistry and cellular processing of EGF-dextran. Acta Oncol 38 (1999) 313-321
32. Raben D., Helfrich B., Chan D.C., Ciardiello F., Zhao L., Franklin W., et al. The effects of cetuximab alone and in combination with radiation and/or chemotherapy in lung cancer. Clin Cancer Res 11 (2005) 795-805
33. Fan Z., Lu Y., Wu X., and Mendelsohn J. Antibody-induced epidermal growth factor receptor dimerization mediates inhibition of autocrine proliferation of A431 squamous carcinoma cells. J Biol Chem 269 (1994) 27595-27602
34. Sznajder J.I., Ridge K.M., Yeates D.B., Ilekis J., and Olivera W. Epidermal growth factor increases lung liquid clearance in rat lungs. J Appl Physiol 85 (1998) 1004-1010
35. Nie S., Xing Y., Kim G.J., and Simons J.W. Nanotechnology applications in cancer. Annu Rev Biomed Eng 9 (2007) 257-288
36. Hoet P.H., Hohlfeld I.B., and Salata O.V. Nanoparticles - known and unknown health risks. J Nanobiotechnol 2 (2004) 1-15
37. Otsuka H., Nagasaki Y., and Kataoka K. PEGylated nanoparticles for biological and pharmaceutical applications. Adv Drug Deliv Rev 55 (2003) 403-419